Cue Biopharma Stock Probability of Future Stock Price Finishing Over 35.06
| CUE Stock | USD 1.11 0.04 3.74% |
Cue |
Cue Biopharma Target Price Odds to finish over 35.06
The tendency of Cue Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 35.06 or more in 90 days |
| 1.11 | 90 days | 35.06 | close to zero percent |
Based on a normal probability distribution, the odds of Cue Biopharma to move over $ 35.06 or more in 90 days from now is close to zero percent (This Cue Biopharma probability density function shows the probability of Cue Stock to fall within a particular range of prices over 90 days) . Probability of Cue Biopharma price to stay between its current price of $ 1.11 and $ 35.06 at the end of the 90-day period is nearly 4.32 .
Considering the 90-day investment horizon the stock has the beta coefficient of 1.23 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Cue Biopharma will likely underperform. Additionally Cue Biopharma has an alpha of 0.5998, implying that it can generate a 0.6 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Cue Biopharma Price Density |
| Price |
Predictive Modules for Cue Biopharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Cue Biopharma. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Cue Biopharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Cue Biopharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Cue Biopharma is not an exception. The market had few large corrections towards the Cue Biopharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Cue Biopharma, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Cue Biopharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.60 | |
β | Beta against Dow Jones | 1.23 | |
σ | Overall volatility | 0.21 | |
Ir | Information ratio | 0.06 |
Cue Biopharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Cue Biopharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Cue Biopharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Cue Biopharma is way too risky over 90 days horizon | |
| Cue Biopharma may become a speculative penny stock | |
| Cue Biopharma appears to be risky and price may revert if volatility continues | |
| Cue Biopharma has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the last year's revenue of 5.49 M. Reported Net Loss for the year was (50.73 M) with profit before taxes, overhead, and interest of 1.25 M. | |
| Cue Biopharma has about 66.13 M in cash with (39.96 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.87, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Cue Biopharma has a frail financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Acquisition by Sandercock Colin of 100000 shares of Cue Biopharma at 3.21 subject to Rule 16b-3 |
Cue Biopharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Cue Stock often depends not only on the future outlook of the current and potential Cue Biopharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Cue Biopharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 45.8 M | |
| Cash And Short Term Investments | 48.5 M |
Cue Biopharma Technical Analysis
Cue Biopharma's future price can be derived by breaking down and analyzing its technical indicators over time. Cue Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Cue Biopharma. In general, you should focus on analyzing Cue Stock price patterns and their correlations with different microeconomic environments and drivers.
Cue Biopharma Predictive Forecast Models
Cue Biopharma's time-series forecasting models is one of many Cue Biopharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Cue Biopharma's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Cue Biopharma
Checking the ongoing alerts about Cue Biopharma for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Cue Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Cue Biopharma is way too risky over 90 days horizon | |
| Cue Biopharma may become a speculative penny stock | |
| Cue Biopharma appears to be risky and price may revert if volatility continues | |
| Cue Biopharma has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the last year's revenue of 5.49 M. Reported Net Loss for the year was (50.73 M) with profit before taxes, overhead, and interest of 1.25 M. | |
| Cue Biopharma has about 66.13 M in cash with (39.96 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.87, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Cue Biopharma has a frail financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Acquisition by Sandercock Colin of 100000 shares of Cue Biopharma at 3.21 subject to Rule 16b-3 |
Check out Cue Biopharma Backtesting, Cue Biopharma Valuation, Cue Biopharma Correlation, Cue Biopharma Hype Analysis, Cue Biopharma Volatility, Cue Biopharma History as well as Cue Biopharma Performance. For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cue Biopharma. If investors know Cue will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cue Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.97) | Revenue Per Share 0.172 | Quarterly Revenue Growth 0.923 | Return On Assets (0.52) | Return On Equity (1.39) |
The market value of Cue Biopharma is measured differently than its book value, which is the value of Cue that is recorded on the company's balance sheet. Investors also form their own opinion of Cue Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Cue Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cue Biopharma's market value can be influenced by many factors that don't directly affect Cue Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cue Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cue Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cue Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.